ReviewTranslational neurodegeneration2021
COVID-19 and Alzheimer's disease: how one crisis worsens the other.
Review in Translational neurodegeneration, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 144 citations in OpenAlex.
- Pooled it
- Meta-Analysis of APP Expression Modulated by SARS-CoV-2 Infection via the ACE2 Receptor.International journal of molecular sciences · 2022Pooled it
- Disease burden of viral respiratory infections in people with intellectual disabilities: a scoping review.BMJ open respiratory research · 2026Article
- Identification of Shared Gene Signatures Associated with Alzheimer's Disease and COVID-19 through Bioinformatics Analysis.Combinatorial chemistry & high throughput screening · 2026Article
- Associations between neutrophil-lymphocyte ratio and risk of cognitive impairment among Chinese older adults.BMC geriatrics · 2025Article
- Mortality for Alzheimer's disease during the COVID-19 pandemic.European geriatric medicine · 2025Article
- Gender-based Alzheimer's detection using ResNet-50 and binary dragonfly algorithm on neuroimaging.Frontiers in artificial intelligence · 2025Article
- Article
- Article
- Underestimated virus impaired cognition-more evidence and more work to do.Frontiers in immunology · 2025Review
- The Expanding Burden of Neurodegenerative Diseases: An Unmet Medical and Social Need.Aging and disease · 2024Review
- Genome-wide association studies of COVID-19 vaccine seroconversion and breakthrough outcomes in UK Biobank.Nature communications · 2024Article
- Decoding the genetic comorbidity network of Alzheimer's disease.BioData mining · 2024Article
- Current Advances and Future Perspectives on Mesenchymal Stem Cell-Derived Extracellular Vesicles in Alzheimer's Disease.Aging and disease · 2024Review
- The Influence of SARS-CoV-2 Infection on the Development of Selected Neurological Diseases.International journal of molecular sciences · 2024Review
- Identifying the Interaction Between Tuberculosis and SARS-CoV-2 Infections via Bioinformatics Analysis and Machine Learning.Biochemical genetics · 2024Article
- Molecular cross-talk between long COVID-19 and Alzheimer's disease.GeroScience · 2024Review
- Network analysis-guided drug repurposing strategies targeting LPAR receptor in the interplay of COVID, Alzheimer's, and diabetes.Scientific reports · 2024Article
- Investigating the Potential Shared Molecular Mechanisms between COVID-19 and Alzheimer's Disease via Transcriptomic Analysis.Viruses · 2024Article
- hdWGCNA and Cellular Communication Identify Active NK Cell Subtypes in Alzheimer's Disease and Screen for Diagnostic Markers through Machine Learning.Current Alzheimer research · 2024Article
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 2 countries.
Funding
Abstract
Alzheimer's disease (AD) has emerged as a key comorbidity of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The morbidity and mortality of COVID-19 are elevated in AD due to multiple pathological changes in AD patients such as the excessive expression of viral receptor angiotensin converting enzyme 2 and pro-inflammatory molecules, various AD complications including diabetes, lifestyle alterations in AD, and drug-drug interactions. Meanwhile, COVID-19 has also been reported to cause various neurologic symptoms including cognitive impairment that may ultimately result in AD, probably through the invasion of SARS-CoV-2 into the central nervous system, COVID-19-induced inflammation, long-term hospitalization and delirium, and post-COVID-19 syndrome. In addition, the COVID-19 crisis also worsens behavioral symptoms in uninfected AD patients and poses new challenges for AD prevention. In this review, we first introduce the symptoms and pathogenesis of COVID-19 and AD. Next, we provide a comprehensive discussion on the aggravating effects of AD on COVID-19 and the underlying mechanisms from molecular to social levels. We also highlight the influence of COVID-19 on cognitive function, and propose possible routes of viral invasion into the brain and potential mechanisms underlying the COVID-19-induced cognitive impairment. Last, we summarize the negative impacts of COVID-19 pandemic on uninfected AD patients and dementia prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.